Top

Diabetes Therapy

Published in:

Open Access 14-09-2023 | Hypoglycemia | Review

Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia

Authors: Marga Giménez, Kamlesh Khunti, Munehide Matsuhisa, Suresh Chenji, Kristen Syring, Yu Yan

Published in: Diabetes Therapy | Issue 11/2023

Abstract

Introduction

Ready-to-use glucagon represents a significant advancement in the management of severe hypoglycemia for people with diabetes and their caregivers. This indirect treatment comparison (ITC) evaluated the efficacy and safety differences among the three ready-to-use glucagon treatments, Baqsimi^® (nasal glucagon), Gvoke^® (glucagon injection) and Zegalogue^® (dasiglucagon injection), in adults and children with type 1 diabetes (T1D) or type 2 diabetes (T2D).

Methods

A systematic literature review was conducted to identify randomized clinical trials assessing the efficacy and safety of Baqsimi, Gvoke or Zegalogue versus reconstituted, injectable glucagon (IG) in reversing insulin-induced hypoglycemia. Bayesian fixed-effect network meta-analysis was used to perform the ITC. Study endpoints included proportion of participants achieving treatment success, maximum blood glucose achieved, time to achieve treatment success and maximum blood glucose and treatment-emergent adverse events (TEAE).

Results

Ten clinical trials were included in the ITC (four for Baqsimi, three for Gvoke, and three for Zegalogue). All three treatments achieved high proportions of treatment success (> 98%). In adults, the efficacy results from combined T1D and T2D analysis were consistent with the T1D analysis, except statistically significantly faster in achieving treatment success for Baqsimi vs Gvoke in the combined analysis (13.96 vs 14.66 min). The mean maximum blood glucose values were also statistically significantly lower for Baqsimi (168 mg/dl) vs Gvoke (220 mg/dl) and Zegalogue (190 mg/dl). There was a trend towards a lower number of adults experiencing ≥ 1 TEAE with Baqsimi compared to Gvoke or Zegalogue, but no statistical significance was reached.

Conclusion

Baqsimi, Gvoke and Zegalogue had comparable high proportions of treatment success in reversing insulin-induced hypoglycemia. Baqsimi achieved a lower mean maximum blood glucose value, which may have implications for the re-establishment of euglycemia. These findings may help support patients, caregivers and health care providers in their decision-making process when discussing various ready-to-use glucagon treatment options.

Available only for authorised users

Khunti K, Alsifri S, Aronson R, Cigrovski Berković M, Enters-Weijnen C, Forsén T, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907–15. https://doi.org/10.1111/dom.12689.CrossRefPubMedPubMedCentral

Snoek FJ, Spaepen E, Nambu BA, Child CJ, Bajpai S, Balantac Z, et al. Conversations and reactions around severe hypoglycemia (CRASH) study: results from people with diabetes and caregivers in the United States. Clin Diabetes. 2022;40(4):477–88. https://doi.org/10.2337/cd21-0131.CrossRefPubMedPubMedCentral

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. Glycemic targets: standards of care in diabetes—2023. Diabetes Care. 2022;46(Supplement_1):S97–110. https://doi.org/10.2337/dc23-S006.CrossRefPubMedCentral

Yun JS, Ko SH. Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J. 2016;40(6):423–32. https://doi.org/10.4093/dmj.2016.40.6.423.CrossRefPubMedPubMedCentral

Lacy ME, Gilsanz P, Eng C, Beeri MS, Karter AJ, Whitmer RA. Severe hypoglycemia and cognitive function in older adults with type 1 diabetes: the study of longevity in diabetes (SOLID). Diabetes Care. 2020;43(3):541–8. https://doi.org/10.2337/dc19-0906.CrossRefPubMedPubMedCentral

McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35(9):1897–901. https://doi.org/10.2337/dc11-2054.CrossRefPubMedPubMedCentral

Yale JF, Dulude H, Egeth M, Piché CA, Lafontaine M, Carballo D, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: a simulation study. Diabetes Technol Ther. 2017;19(7):423–32. https://doi.org/10.1089/dia.2016.0460.CrossRefPubMedPubMedCentral

Settles JA, Gerety GF, Spaepen E, Suico JG, Child CJ. Nasal glucagon delivery is more successful than injectable delivery: a simulated severe hypoglycemia rescue. Endocr Pract. 2020;26(4):407–15. https://doi.org/10.4158/ep-2019-0502.CrossRefPubMed

Muradoğlu S, Yeşiltepe Mutlu G, Gökçe T, Can E, Hatun Ş. An evaluation of glucagon injection anxiety and its association with the fear of hypoglycemia among the parents of children with type 1 diabetes. J Clin Res Pediatr Endocrinol. 2021;13(3):285–92. https://doi.org/10.4274/jcrpe.galenos.2021.2020.0191.CrossRefPubMedPubMedCentral

10.

Kahn PA, Liu S, McCoy R, Gabbay RA, Lipska K. Glucagon use by U.S. adults with type 1 and type 2 diabetes. J Diabetes Complications. 2021;35(5):107882. https://doi.org/10.1016/j.jdiacomp.2021.107882.CrossRefPubMed

11.

Baqsimi^® (glucagon). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210134s000lbl.pdf. Accessed 26 Apr 2023.

12.

Gvoke^® (glucagon). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212097s000lbl.pdf. Accessed 26 Apr 2023.

13.

Zegalogue^® (dasiglucagon). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf. Accessed 26 Apr 2023.

14.

Matsuhisa M, Takita Y, Nasu R, Nagai Y, Ohwaki K, Nagashima H. Nasal glucagon as a viable alternative for treating insulin-induced hypoglycaemia in Japanese patients with type 1 or type 2 diabetes: a phase 3 randomized crossover study. Diabetes Obes Metab. 2020;22(7):1167–75. https://doi.org/10.1111/dom.14019.CrossRefPubMedPubMedCentral

15.

Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, et al. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555–62. https://doi.org/10.2337/dc15-1606.CrossRefPubMedPubMedCentral

16.

Suico JG, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, et al. Glucagon administration by nasal and intramuscular routes in adults with type 1 diabetes during insulin-induced hypoglycaemia: a randomised, open-label, crossover study. Diabetes Ther. 2020;11(7):1591–603. https://doi.org/10.1007/s13300-020-00845-7.CrossRefPubMedPubMedCentral

17.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264–70. https://doi.org/10.2337/dc15-1498.CrossRefPubMed

18.

Christiansen MP, Cummins M, Prestrelski S, Close NC, Nguyen A, Junaidi K. Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies. BMJ Open Diabetes Res Care. 2021. https://doi.org/10.1136/bmjdrc-2021-002137.CrossRefPubMedPubMedCentral

19.

Pieber TR, Aronson R, Christiansen MP, Bode B, Junaidi K, Conoscenti V. Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready-to-use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin-induced severe hypoglycaemia in adults with type 1 diabetes. Diabetes Obes Metab. 2022;24(7):1394–7.CrossRefPubMed

20.

Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, et al. Dasiglucagon-a next-generation glucagon analog for rapid and effective treatment of severe hypoglycemia: results of phase 3 randomized double-blind clinical trial. Diabetes Care. 2021;44(6):1361–7. https://doi.org/10.2337/dc20-2995.CrossRefPubMedPubMedCentral

21.

Hövelmann U, Bysted BV, Mouritzen U, Macchi F, Lamers D, Kronshage B, et al. Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog. Diabetes Care. 2018;41(3):531–7. https://doi.org/10.2337/dc17-1402.CrossRefPubMed

22.

Battelino T, Tehranchi R, Bailey T, Dovc K, Melgaard A, Yager Stone J, et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: results of a phase 3, randomized controlled trial. Pediatr Diabetes. 2021;22(5):734–41. https://doi.org/10.1111/pedi.13220.CrossRefPubMedPubMedCentral

23.

Yale JF, Paty B, Senior PA. Hypoglycemia - 2018 clinical practice guidelines. Can J Diabetes. 2018;42(Suppl 1):S104–8. https://doi.org/10.1016/j.jcjd.2017.10.010.CrossRefPubMed

24.

Yan Y, Wang Q, Child CJ, Zhang MX. 1085-P: nasal glucagon was efficacious in reversing insulin-induced hypoglycemia without increasing risk of secondary hyperglycemia. Diabetes. 2020. https://doi.org/10.2337/db20-1085-P.CrossRefPubMedPubMedCentral

25.

Giménez M, Yan Y, Wang Q, Child CJ, Zhang M. Nasal glucagon was efficacious in reversing insulin-induced hypoglycaemia without increasing risk of secondary hyperglycaemia. EASD Conference. 2020.

26.

Valentine V, Newswanger B, Prestrelski S, Andre AD, Garibaldi M. Human factors usability and validation studies of a glucagon autoinjector in a simulated severe hypoglycemia rescue situation. Diabetes Technol Ther. 2019;21(9):522–30. https://doi.org/10.1089/dia.2019.0148.CrossRefPubMedPubMedCentral

27.

Bailey NC, Dimsits J, Hammer M, Kendall DM, Bailey TS. A comparative study of dasiglucagon ready-to-use autoinjector and glucagon emergency kit during rescue from simulated severe hypoglycemia. Diabetes Technol Ther. 2022;24(4):231–40. https://doi.org/10.1089/dia.2021.0367.CrossRefPubMedPubMedCentral

28.

Mitchell BD, Rentz AM, Kummer S, Yan Y, Heidenreich S, Krucien N, et al. People with diabetes and caregivers prefer rescue glucagon treatment with a wider storage temperature range and a nasal administration, when efficacy is similar: a discrete choice experiment in Spain. J Diabetes Sci Technol. 2022. https://doi.org/10.1177/19322968221095882.CrossRefPubMed

Title: Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia
Authors: Marga Giménez
Kamlesh Khunti
Munehide Matsuhisa
Suresh Chenji
Kristen Syring
Yu Yan
Publication date: 14-09-2023
Publisher: Springer Healthcare
Keywords: Hypoglycemia
Type 1 Diabetes
Type 2 Diabetes
Published in: Diabetes Therapy / Issue 11/2023
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-023-01466-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2023

Optimising Insulin Injection Techniques to Improve Diabetes Outcomes

A Longitudinal Clinical Trajectory Analysis Examining the Accumulation of Co-morbidity in People with Type 2 Diabetes (T2D) Compared with Non-T2D Individuals

Simplification of Complex Insulin Regimens with IdegLira in People with Type 2 Diabetes: Literature Review and Clinical Recommendations

Insulin Therapy for the Management of Diabetes Mellitus: A Narrative Review of Innovative Treatment Strategies

Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme

Correction to: Prevalence of Diabetic Kidney Disease with Different Subtypes in Hospitalized Patients with Diabetes and Correlation Between eGFR and LncRNA XIST Expression in PBMCs

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials